

Marco Russano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5728264/publications.pdf>

Version: 2024-02-01

43
papers

1,845
citations

471509

17
h-index

361022

35
g-index

47
all docs

47
docs citations

47
times ranked

3129
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 123-132.	1.5	1
2	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
3	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	17.0	5
4	Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e137-e138.	2.6	0
5	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
6	Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. <i>Cancers</i> , 2021, 13, 652.	3.7	19
7	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	1.9	30
8	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
9	Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations. <i>Thoracic Cancer</i> , 2021, 12, 1791-1792.	1.9	0
10	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. <i>European Journal of Cancer</i> , 2021, 148, 24-35.	2.8	19
11	Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	2.8	24
12	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	4.4	14
13	Exploring the role of respiratory microbiome in lung cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103404.	4.4	18
14	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
15	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	2.0	13
16	Denosumab for cancer-related bone loss. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1261-1274.	3.1	12
17	Steroid-refractory immune related hepatitis may hide viral re-activation. <i>Future Science OA</i> , 2020, 6, FSO614.	1.9	2
18	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126

#	ARTICLE	IF	CITATIONS
19	Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 95.	8.6	147
20	Facing SARS-CoV-2 outbreak in immunotherapy era. <i>Future Oncology</i> , 2020, 16, 1475-1485.	2.4	9
21	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression \geq 50% and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
22	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	2.8	85
23	COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 959-964.	3.1	18
24	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	3.1	12
25	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020, 37, 1145-1155.	2.9	102
26	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolmunology</i> , 2020, 9, 1710389.	4.6	9
27	Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?. <i>Journal of Thoracic Oncology</i> , 2020, 15, e105-e106.	1.1	12
28	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
29	Prognostic and predictive factors in pancreatic cancer. <i>Oncotarget</i> , 2020, 11, 924-941.	1.8	46
30	Cabozantinib and apixaban: an hitherto unreported interaction. <i>Experimental Hematology and Oncology</i> , 2019, 8, 22.	5.0	7
31	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337.	3.7	131
32	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
33	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	2.6	118
34	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37.	2.4	5
35	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	3.1	85
36	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	3.7	27

#	ARTICLE	IF	CITATIONS
37	Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib. <i>Oncotarget</i> , 2017, 8, 59986-59990.	1.8	11
38	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. <i>PLoS ONE</i> , 2016, 11, e0157751.	2.5	17
39	Pazopanib and pancreatic toxicity: a case report. <i>BMC Research Notes</i> , 2015, 8, 196.	1.4	9
40	Impact of Smoking Cessation Treatment on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2015, 10, 342-351.	1.6	8
41	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014, 110, 2165-2169.	6.4	69
42	'Old' and 'new' drugs for the treatment of cancer pain. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 425-433.	1.8	6
43	Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. <i>Supportive Care in Cancer</i> , 2013, 21, 2955-2956.	2.2	8